Telbivudine

Drug Profile

Telbivudine

Alternative Names: 2'-deoxy-L-thymidine; B-L-thymidine; Beta-L-thymidine; Epavudine; L-dT; LDT-600; NV-02B; Sebivo; Tyzeka

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centre National de la Recherche Scientifique; Idenix Pharmaceuticals; University of Montpellier II
  • Developer Novartis
  • Class Antivirals; Nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 20 Jul 2017 Telbivudine is still in phase III trials for Hepatitis B (In children, In adolescents) in Ukraine, Romania, South Korea, Israel, Bulgaria, Greece, Turkey and United Kingdom (PO) (NCT02058108)
  • 15 Mar 2016 Biomarkers information updated
  • 16 Jun 2015 Launched for Hepatitis B in Croatia, Finland, Georgia, Latvia, Lithuania, Romania, Oman, Serbia, Armenia, Singapore, Slovakia, Slovenia, South Africa, Taiwan, Venezuela, Estonia, Malta, Hungary, Bahrain, Saudi Arabia, Qatar, Jordan, Nigeria, Sri Lanka, India and Bangladesh (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top